| Literature DB >> 31877321 |
Vasiliki Panagiotakopoulou1, Konstantinos Botsakis2, Foteini Delis3, Theodora Mourtzi1, Manolis N Tzatzarakis4, Aggeliki Dimopoulou2, Nafsika Poulia3, Katerina Antoniou3, Georgios T Stathopoulos2, Nikolaos Matsokis1, Ioannis Charalampopoulos5, Achilleas Gravanis5, Fevronia Angelatou6.
Abstract
BNN-20 is a synthetic microneurotrophin, long-term (P1-P21) administration of which exerts potent neuroprotective effect on the "weaver" mouse, a genetic model of progressive, nigrostriatal dopaminergic degeneration. The present study complements and expands our previous work, providing evidence that BNN-20 fully protects the dopaminergic neurons even when administration begins at a late stage of dopaminergic degeneration (>40%). Since neuroinflammation plays a critical role in Parkinson's disease, we investigated the possible anti-neuroinflammatory mechanisms underlying the pharmacological action of BNN-20. The latter was shown to be microglia-mediated, at least in part. Indeed, BNN-20 induced a partial, but significant, reversal of microglia hyperactivation, observed in the untreated "weaver" mouse. Furthermore, it induced a shift in microglia polarization towards the neuroprotective M2 phenotype, suggesting a possible beneficial shifting of microglia activity. This observation was further supported by morphometric measurements. Moreover, BDNF levels, which were severely reduced in the "weaver" mouse midbrain, were restored to normal even after short-term BNN-20 administration. Experiments in "weaver"/NGL (dual GFP/luciferase-NF-κВ reporter) mice using bioluminescence after a short BNN-20 treatment (P60-P74), have shown that the increase of BDNF production was specifically mediated through the TrkB-PI3K-Akt-NF-κB signaling pathway. Interestingly, long-term BNN-20 treatment (P14-P60) significantly increased dopamine levels in the "weaver" striatum, which seems to be associated with the improved motor activity observed in the treated mutant animals. In conclusion, our findings suggest that BNN-20 may serve as a lead molecule for new therapeutic compounds for Parkinson's disease, combining strong anti-neuroinflammatory and neuroprotective properties, leading to elevated dopamine levels and improved motor activity.Entities:
Keywords: BDNF production; Microglia-polarization; Microneurotrophin; Neuroprotection
Year: 2019 PMID: 31877321 DOI: 10.1016/j.neuropharm.2019.107919
Source DB: PubMed Journal: Neuropharmacology ISSN: 0028-3908 Impact factor: 5.250